All News

BP.jpg

Resistant Hypertension Common in SLE

d RheumNow

Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.

Read Article
renal.genes_.jpg

Improved Mortality Trends in Lupus Nephritis

d Jack Cush, MD

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Read Article
narcotics_0.jpg

Risky Painkillers Commonly Prescribed for Osteoarthritis

d RheumNow

Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling.

Read Article
Kawasaki.jpg

Cyclosporin and IVIG Effective in Kawasaki's Disease

d Jack Cush, MD

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Read Article
gout.bunion.jpg

Ironwood Retreats from the US Gout Market

d Jack Cush, MD

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.

Read Article
cancer.cross_.jpg

No Rise in Cancer Risk with Actemra

d RheumNow

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

Read Article
AAOS meeting presentation of 114,698 TKR pts shows younger pts (age <40) have a 3 fold greater risk of early mechanical complications & are 63% more likely to be rehospitalized w/in 90D. Younger have more obesity, DM, inflamm arthritis, ACL surgery https://t.co/DoePD5GXl9

Links:

Dr. John Cush RheumNow ( View Tweet)

The risk of acute coronary syndromes in inflammatory myositis patients is doubled, especially in the first year (vs general population) and in older individuals. (HR 2.4; 1.8-3.2) - 7% IIM vs 3.3% in controls at 5 yrs. https://t.co/lCWGfm81EN

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Goldilocks and Osteoarthritis | RheumNow - Finding the Right Ddose for the Right Patient? https://t.co/SMmVYDxPeX

Links:

Dr. John Cush RheumNow ( View Tweet)

FREE Online viewing of RheumNow Live - Friday 3/22 at 1pm EST. 2 hr discussion blocks on RA, PsA, AS, SLE, Vasculitis. 10 "TED" talks interspersed from Cush, Calabrese, Van Vollenhoven, Schett, Matteson, Wolfe, Oransky,etc. SEE YOU THERE OR REGISTER HERE https://t.co/lbrJ0Dp1Hb

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologists are the happiest specialists! https://t.co/C6aaHWq7qf @ACRheum Choose Rheumatology and Be Happy! @alhkim

Links:

Jeff Sparks jeffsparks ( View Tweet)

Study of 151,305 pts from Clinical Practice Research Datalink, shows that THR/TKR patients exposed to statins for 1-5 years had ~25% reduced risk of arthroplasty revision (HR 0.74 (0.62, 0.88)). https://t.co/AQhKHuAwkD

Links:

Dr. John Cush RheumNow ( View Tweet)

Pain signaling via NMDA receptors in the brain can be treated with drugs that block NMDA receptors (ketamine, methadone, memantine, amantadine, dextromethorphan). Metanalysis of memantine (15 studies) shows little benefit. https://t.co/72yfYzDXhV

Links:

Dr. John Cush RheumNow ( View Tweet)

Brain fog (Fibro Fog) is common with sleep disorders and fibromyalgia. Manifests as memory problems, poor mental focus, forgetfulness - all correctable with sleep medicine evaluation and sleep assistance. https://t.co/e6CXXkYV39

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 21,016 SLE patients from Korean Health Claims databases shows SLE patients have a higher risk of cancer than controls (OR 1.44; 95% CI 1.33–1.56) with highre rates of cervical, thyroid, ovarian, oral cancer, lymphoma, leukemia, & multiple myeloma https://t.co/NKR9i4ccfU

Links:

Dr. John Cush RheumNow ( View Tweet)

Time to register for this weeks RheumNow Live. Free online streaming video - 16 hrs of Innovative lectures and Q&A Panels from friday afternoon 3/22, till noon Sunday 3/24. Register for FREE at https://t.co/wIgS5rq4UE

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - When To Stop MTX- Should/Can a Patient ever stop MTX? | RheumNow https://t.co/z0Dhwdbr3Q

Links:

Dr. John Cush RheumNow ( View Tweet)

European Commission Approves MabThera (rituximab) for use in Pemphigus, US FDA approved it in 6/18; RTX is now approved in 4 autoimmune disorders in the US & Europe (RA, GPA, MPA, Pemphigus) - Not approved for use in children https://t.co/dJJfPdXuWQ(rituxim/364143/index.html

Links:

Dr. John Cush RheumNow ( View Tweet)

Nice comprehensive full read review of the Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline from the JBMR. https://t.co/Eh9xfPJ2B0

Links:

Dr. John Cush RheumNow ( View Tweet)

Vedolizumab superior to adalimumab in clinical remission (31 vs 22%) and mucosal healing(40 vs 28%) at week 52 when given to383 patients with moderate to severely active ulcerative colitis. Data presented at European Crohn’s and Colitis Congress. https://t.co/dXrEkzhnKh

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×